Skip to main content
PMC home page
Journal of Medical Genetics logoLink to Journal of Medical Genetics
. 2000 Dec;37(12):939–943. doi: 10.1136/jmg.37.12.939

Cryptic von Hippel-Lindau disease: germline mutations in patients with haemangioblastoma only

F Hes 1, S McKee 1, M Taphoorn 1, P Rehal 1, R B van der Luijt 1, R McMahon 1, J J van der Smagt 1, D Dow 1, R Zewald 1, J Whittaker 1, C Lips 1, F MacDonald 1, P Pearson 1, E Maher 1
PMCID: PMC1734505  PMID: 11106358

Abstract

OBJECTIVES— Central nervous system haemangioblastoma (HAB) is a major feature of von Hippel-Lindau (VHL) disease, and it is estimated that about 30% of HAB patients have VHL disease. Consequently, it is widely recommended that sporadic HAB patients are screened for clinical and radiological features of VHL disease because of the risk of multiple tumours. We investigated the frequency of VHL germline mutations in patients with HAB only with no clinical or radiological evidence of VHL disease to define the role of molecular genetic analysis in the management of such patients.
METHODS—Eighty four patients with a single HAB (23 Dutch, 61 UK) and four with multiple HAB (two Dutch, two UK) were studied by direct sequencing of the coding region and quantitative Southern blotting.
RESULTS—A VHL germline mutation was found in three of 69 (4.3%) single HAB patients aged 50 years or less (three of 84 (3.6%) total single HAB patients). A germline VHL mutation was detected in a 44 year old woman with a solitary cerebellar HAB, as well as in four clinically unaffected close relatives, and in two single HAB cases presenting at the ages of 29 and 36 years. Germline VHL mutations were detected in two of four cases with multiple HAB.
CONCLUSIONS—Early detection of VHL disease is important to reduce morbidity and mortality and therefore we recommend that, in addition to conventional clinical and radiological investigations, VHL gene mutation analysis should be offered to all HAB patients younger than 50 years. HAB patients aged >50 years will have a lower a priori risk of VHL disease and further data are required to evaluate the role of routine molecular genetic investigations in late onset HAB cases. The failure to detect germline VHL mutations in some patients with multiple HAB may indicate the presence of somatic mosaicism or additional HAB susceptibility genes.


Keywords: haemangioblastoma; von Hippel-Lindau disease; VHL; germline mutation

Full Text

The Full Text of this article is available as a PDF (141.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brauch H., Kishida T., Glavac D., Chen F., Pausch F., Höfler H., Latif F., Lerman M. I., Zbar B., Neumann H. P. Von Hippel-Lindau (VHL) disease with pheochromocytoma in the Black Forest region of Germany: evidence for a founder effect. Hum Genet. 1995 May;95(5):551–556. doi: 10.1007/BF00223868. [DOI] [PubMed] [Google Scholar]
  2. Chang S. D., Meisel J. A., Hancock S. L., Martin D. P., McManus M., Adler J. R., Jr Treatment of hemangioblastomas in von Hippel-Lindau disease with linear accelerator-based radiosurgery. Neurosurgery. 1998 Jul;43(1):28–35. doi: 10.1097/00006123-199807000-00018. [DOI] [PubMed] [Google Scholar]
  3. Chen F., Slife L., Kishida T., Mulvihill J., Tisherman S. E., Zbar B. Genotype-phenotype correlation in von Hippel-Lindau disease: identification of a mutation associated with VHL type 2A. J Med Genet. 1996 Aug;33(8):716–717. doi: 10.1136/jmg.33.8.716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Crossey P. A., Eng C., Ginalska-Malinowska M., Lennard T. W., Wheeler D. C., Ponder B. A., Maher E. R. Molecular genetic diagnosis of von Hippel-Lindau disease in familial phaeochromocytoma. J Med Genet. 1995 Nov;32(11):885–886. doi: 10.1136/jmg.32.11.885. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Crossey P. A., Richards F. M., Foster K., Green J. S., Prowse A., Latif F., Lerman M. I., Zbar B., Affara N. A., Ferguson-Smith M. A. Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. Hum Mol Genet. 1994 Aug;3(8):1303–1308. doi: 10.1093/hmg/3.8.1303. [DOI] [PubMed] [Google Scholar]
  6. Decker H. J., Neuhaus C., Jauch A., Speicher M., Ried T., Bujard M., Brauch H., Störkel S., Stöckle M., Seliger B. Detection of a germline mutation and somatic homozygous loss of the von Hippel-Lindau tumor-suppressor gene in a family with a de novo mutation. A combined genetic study, including cytogenetics, PCR/SSCP, FISH, and CGH. Hum Genet. 1996 Jun;97(6):770–776. doi: 10.1007/BF02346188. [DOI] [PubMed] [Google Scholar]
  7. Evans D. G., Wallace A. J., Wu C. L., Trueman L., Ramsden R. T., Strachan T. Somatic mosaicism: a common cause of classic disease in tumor-prone syndromes? Lessons from type 2 neurofibromatosis. Am J Hum Genet. 1998 Sep;63(3):727–736. doi: 10.1086/512074. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gnarra J. R., Tory K., Weng Y., Schmidt L., Wei M. H., Li H., Latif F., Liu S., Chen F., Duh F. M. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet. 1994 May;7(1):85–90. doi: 10.1038/ng0594-85. [DOI] [PubMed] [Google Scholar]
  9. Huson S. M., Harper P. S., Hourihan M. D., Cole G., Weeks R. D., Compston D. A. Cerebellar haemangioblastoma and von Hippel-Lindau disease. Brain. 1986 Dec;109(Pt 6):1297–1310. doi: 10.1093/brain/109.6.1297. [DOI] [PubMed] [Google Scholar]
  10. Latif F., Tory K., Gnarra J., Yao M., Duh F. M., Orcutt M. L., Stackhouse T., Kuzmin I., Modi W., Geil L. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993 May 28;260(5112):1317–1320. doi: 10.1126/science.8493574. [DOI] [PubMed] [Google Scholar]
  11. Lee J. Y., Dong S. M., Park W. S., Yoo N. J., Kim C. S., Jang J. J., Chi J. G., Zbar B., Lubensky I. A., Linehan W. M. Loss of heterozygosity and somatic mutations of the VHL tumor suppressor gene in sporadic cerebellar hemangioblastomas. Cancer Res. 1998 Feb 1;58(3):504–508. [PubMed] [Google Scholar]
  12. MELMON K. L., ROSEN S. W. LINDAU'S DISEASE. REVIEW OF THE LITERATURE AND STUDY OF A LARGE KINDRED. Am J Med. 1964 Apr;36:595–617. doi: 10.1016/0002-9343(64)90107-x. [DOI] [PubMed] [Google Scholar]
  13. Maher E. R., Iselius L., Yates J. R., Littler M., Benjamin C., Harris R., Sampson J., Williams A., Ferguson-Smith M. A., Morton N. Von Hippel-Lindau disease: a genetic study. J Med Genet. 1991 Jul;28(7):443–447. doi: 10.1136/jmg.28.7.443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Maher E. R., Kaelin W. G., Jr von Hippel-Lindau disease. Medicine (Baltimore) 1997 Nov;76(6):381–391. doi: 10.1097/00005792-199711000-00001. [DOI] [PubMed] [Google Scholar]
  15. Maher E. R., Webster A. R., Richards F. M., Green J. S., Crossey P. A., Payne S. J., Moore A. T. Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations. J Med Genet. 1996 Apr;33(4):328–332. doi: 10.1136/jmg.33.4.328. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Maher E. R., Yates J. R., Ferguson-Smith M. A. Statistical analysis of the two stage mutation model in von Hippel-Lindau disease, and in sporadic cerebellar haemangioblastoma and renal cell carcinoma. J Med Genet. 1990 May;27(5):311–314. doi: 10.1136/jmg.27.5.311. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Neumann H. P., Eggert H. R., Weigel K., Friedburg H., Wiestler O. D., Schollmeyer P. Hemangioblastomas of the central nervous system. A 10-year study with special reference to von Hippel-Lindau syndrome. J Neurosurg. 1989 Jan;70(1):24–30. doi: 10.3171/jns.1989.70.1.0024. [DOI] [PubMed] [Google Scholar]
  18. Neumann H. P., Eng C., Mulligan L. M., Glavac D., Zäuner I., Ponder B. A., Crossey P. A., Maher E. R., Brauch H. Consequences of direct genetic testing for germline mutations in the clinical management of families with multiple endocrine neoplasia, type II. JAMA. 1995 Oct 11;274(14):1149–1151. [PubMed] [Google Scholar]
  19. Niemelä M., Lim Y. J., Söderman M., Jäskeläinen J., Lindquist C. Gamma knife radiosurgery in 11 hemangioblastomas. J Neurosurg. 1996 Oct;85(4):591–596. doi: 10.3171/jns.1996.85.4.0591. [DOI] [PubMed] [Google Scholar]
  20. Oberstrass J., Reifenberger G., Reifenberger J., Wechsler W., Collins V. P. Mutation of the Von Hippel-Lindau tumour suppressor gene in capillary haemangioblastomas of the central nervous system. J Pathol. 1996 Jun;179(2):151–156. doi: 10.1002/(sici)1096-9896(199606)179:2<151::aid-path556>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  21. Olschwang S., Richard S., Boisson C., Giraud S., Laurent-Puig P., Resche F., Thomas G. Germline mutation profile of the VHL gene in von Hippel-Lindau disease and in sporadic hemangioblastoma. Hum Mutat. 1998;12(6):424–430. doi: 10.1002/(SICI)1098-1004(1998)12:6<424::AID-HUMU9>3.0.CO;2-H. [DOI] [PubMed] [Google Scholar]
  22. Patrice S. J., Sneed P. K., Flickinger J. C., Shrieve D. C., Pollock B. E., Alexander E., 3rd, Larson D. A., Kondziolka D. S., Gutin P. H., Wara W. M. Radiosurgery for hemangioblastoma: results of a multiinstitutional experience. Int J Radiat Oncol Biol Phys. 1996 Jun 1;35(3):493–499. doi: 10.1016/s0360-3016(96)80011-3. [DOI] [PubMed] [Google Scholar]
  23. Richard S., Beigelman C., Gerber S., Van Effenterre R., Gaudric A., Sahel M., Binaghi M., De Kersaint-Gilly A., Houtteville J. P., Brunon J. P. L'hémangioblastome existe-t-il en dehors de la maladie de von Hippel-Lindau? Neurochirurgie. 1994;40(3):145–154. [PubMed] [Google Scholar]
  24. Richard S., Campello C., Taillandier L., Parker F., Resche F. Haemangioblastoma of the central nervous system in von Hippel-Lindau disease. French VHL Study Group. J Intern Med. 1998 Jun;243(6):547–553. doi: 10.1046/j.1365-2796.1998.00337.x. [DOI] [PubMed] [Google Scholar]
  25. Richards F. M., Payne S. J., Zbar B., Affara N. A., Ferguson-Smith M. A., Maher E. R. Molecular analysis of de novo germline mutations in the von Hippel-Lindau disease gene. Hum Mol Genet. 1995 Nov;4(11):2139–2143. doi: 10.1093/hmg/4.11.2139. [DOI] [PubMed] [Google Scholar]
  26. Sgambati M. T., Stolle C., Choyke P. L., Walther M. M., Zbar B., Linehan W. M., Glenn G. M. Mosaicism in von Hippel-Lindau disease: lessons from kindreds with germline mutations identified in offspring with mosaic parents. Am J Hum Genet. 2000 Jan;66(1):84–91. doi: 10.1086/302726. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Stolle C., Glenn G., Zbar B., Humphrey J. S., Choyke P., Walther M., Pack S., Hurley K., Andrey C., Klausner R. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat. 1998;12(6):417–423. doi: 10.1002/(SICI)1098-1004(1998)12:6<417::AID-HUMU8>3.0.CO;2-K. [DOI] [PubMed] [Google Scholar]
  28. Stratmann R., Krieg M., Haas R., Plate K. H. Putative control of angiogenesis in hemangioblastomas by the von Hippel-Lindau tumor suppressor gene. J Neuropathol Exp Neurol. 1997 Nov;56(11):1242–1252. doi: 10.1097/00005072-199711000-00009. [DOI] [PubMed] [Google Scholar]
  29. Tampieri D., Leblanc R., TerBrugge K. Preoperative embolization of brain and spinal hemangioblastomas. Neurosurgery. 1993 Sep;33(3):502–505. doi: 10.1227/00006123-199309000-00022. [DOI] [PubMed] [Google Scholar]
  30. Vortmeyer A. O., Gnarra J. R., Emmert-Buck M. R., Katz D., Linehan W. M., Oldfield E. H., Zhuang Z. von Hippel-Lindau gene deletion detected in the stromal cell component of a cerebellar hemangioblastoma associated with von Hippel-Lindau disease. Hum Pathol. 1997 May;28(5):540–543. doi: 10.1016/s0046-8177(97)90075-7. [DOI] [PubMed] [Google Scholar]
  31. Webster A. R., Richards F. M., MacRonald F. E., Moore A. T., Maher E. R. An analysis of phenotypic variation in the familial cancer syndrome von Hippel-Lindau disease: evidence for modifier effects. Am J Hum Genet. 1998 Oct;63(4):1025–1035. doi: 10.1086/302037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Wizigmann-Voos S., Plate K. H. Pathology, genetics and cell biology of hemangioblastomas. Histol Histopathol. 1996 Oct;11(4):1049–1061. [PubMed] [Google Scholar]
  33. Woodward E. R., Eng C., McMahon R., Voutilainen R., Affara N. A., Ponder B. A., Maher E. R. Genetic predisposition to phaeochromocytoma: analysis of candidate genes GDNF, RET and VHL. Hum Mol Genet. 1997 Jul;6(7):1051–1056. doi: 10.1093/hmg/6.7.1051. [DOI] [PubMed] [Google Scholar]
  34. Zbar B., Kishida T., Chen F., Schmidt L., Maher E. R., Richards F. M., Crossey P. A., Webster A. R., Affara N. A., Ferguson-Smith M. A. Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat. 1996;8(4):348–357. doi: 10.1002/(SICI)1098-1004(1996)8:4<348::AID-HUMU8>3.0.CO;2-3. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Medical Genetics are provided here courtesy of BMJ Publishing Group

RESOURCES